CytoDyn’s investigational therapy, leronlimab, has shown promising outcomes in treating metastatic triple-negative breast cancer (mTNBC), a disease known for its poor prognosis. Survival rates at 12, 24, and 36 months post-treatment with leronlimab compare favorably to current approved therapies, with some patients surviving over 36 months with no ongoing disease. After resolving a dispute with its former CRO, CytoDyn obtained follow-up records from previous clinical trials, providing further support for leronlimab’s efficacy in oncology.
Read more from benzinga.com
